WebMar 27, 2024 · PRESS RELEASES Cytokinetics, Inc. INVESTORS & MEDIA 2024 Press Releases Webcast 22nd Annual Needham Virtual Healthcare Conference Apr 17, 2024 10:00 AM EDT Keyword Search Press Release Archive 1998-2005 Year 2024 Apr 11 2024 5:00 pm EDT Data Provided by Refinitiv. Minimum 15 minutes delayed. STOCK CHART WebFeb 28, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in …
CYTK Stock Forecast, Price & News (Cytokinetics) - MarketBeat
WebEmail Formats Ashpool's Preflight system has found 2 email formats for Cytokinetics, Inc., @cytokinetics.com has the highest success rate. Note that different roles … WebThe most common Cytokinetics email format is [first_initial][last] (ex. [email protected]), which is being used by 100.0% of Cytokinetics work email addresses. Other common Cytokinetics email patterns are [first] (ex. … great west life dental provider login
Antonio Romero Email & Phone Number - Cytokinet.. ZoomInfo
WebJan 7, 2024 · CYTOKINETICS® and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Royalty Pharma Investor Relations and Communications +1 (212) 883-6772 [email protected] Cytokinetics Contact Joanna Siegall Senior Manager, Corporate Communications, Investor Relations +1 (425) 314-1721 WebFeb 27, 2024 · On Feb. 28, the FDA is set to decide on Cytokinetics ’ omecamtiv mecarbil (OM), a novel, selective cardiac myosin activator being evaluated for heart failure with reduced ejection fraction. The regulatory agency accepted the New Drug Application for OM in February 2024 and initially set a target action date of Nov. 30, 2024. WebFeb 28, 2024 · The US FDA has issued a Complete Response Letter to Cytokinetics (NASDAQ:CYTK) for omecamtiv mecarbil for heart failure with reduced ejection fraction. … great west life dental provider login canada